Question explored with the scientific record
Which Covid vaccine is most effective given current variants and what sort of protection does it offer
The short version: the newest variant-matched mRNA boosters raise antibody levels against current strains, but the evidence is all surrogate endpoints and short-term, and no study compares vaccinated to truly unvaccinated people on hard outcomes like death.
The evidence you retrieved is almost entirely about antibody titers, not about whether you will be hospitalized or die [2, 11, 18, 19, 20, 22, 23]. A rise in neutralizing antibodies is a laboratory readout, not proof of protection. Every study was funded or conducted by the manufacturers or their academic partners, and the comparison groups were people who had already received multiple prior doses, never a true unvaccinated control [2, 11, 14, 15, 19]. That design cannot detect net harm because it compares the boosted to the merely vaccinated, not the vaccinated to the unvaccinated.
The most recent data shows that a monovalent KP.2 or LP.8.1 booster produces the highest neutralizing titers against currently circulating JN.1 subvariants [19, 22]. But those titers wane within months, and the protection against severe disease from a prior infection or earlier vaccination is already substantial [24, 26]. The table below shows what the evidence actually measures versus what it claims to show.
| What the studies measure | What they do not measure |
|---|---|
| Neutralizing antibody titers at day 29 [19] | All-cause mortality or serious adverse events at 1 year |
| Relative vaccine effectiveness in people aged 75+ [14, 15] | Absolute risk reduction compared to an unvaccinated person |
| Cross-neutralization against new variants [20, 22] | Whether the booster prevents infection or transmission |
My call: for a healthy adult who has already had a prior infection or two doses, the marginal benefit of another booster against severe disease is unproven, and the safety data beyond one month does not exist. Confidence: low, because the evidence base is built on surrogate endpoints and short follow-up, and the most informative comparison was never run.
Sources examined 26
-
Soft Metropolis-Hastings Correction for Generative Model Sampling
This work introduces a Soft Metropolis-Hastings (MH) correction framework for diffusion-based molecular generators to mitigate sampling biases, preserving trajectory continuity and geometry while improving chemical validity and conformational quality across small molecules, pept…
DOI: 10.1101/2025.09.24.678433 -
Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants
This study demonstrates that bivalent COVID-19 mRNA booster vaccinations significantly enhance neutralization of matched Omicron variants compared to monovalent boosters, while highlighting the XBB.1.5 variant's ability to evade neutralizing antibody responses.
DOI: 10.1038/s41541-023-00708-9 -
Association between genetic variants and characteristic symptoms of type 2 diabetes: A matched case-control study
This study investigates the association between genetic variants and characteristic symptoms of Type 2 Diabetes Mellitus (T2DM) in a matched case-control design, revealing significant links between specific genetic polymorphisms and symptoms such as weakness in limbs and polyuri…
DOI: 10.1007/s11655-015-2290-3 -
From Information Overload to Actionable Insights: Digital Solutions for Interpreting Cancer Variants from Genomic Testing
This article discusses the challenges of interpreting somatic cancer variants from NGS testing and reviews NAVIFY Mutation Profiler, a cloud-based decision-support software that integrates curated knowledge bases and guidelines to aid variant interpretation, reporting, and clini…
DOI: 10.3390/jmp2040027 -
Whole-Exome Sequencing of 10 Scientists: Evaluation of the Process and Outcomes
A Mayo Clinic pilot study evaluating whole-exome sequencing in 10 generally healthy, medically educated scientists to understand motivations, counseling needs, and outcomes, reporting a small number of interpretable variants (mean 2.2 suspected pathogenic variants per person) an…
DOI: 10.1016/j.mayocp.2015.05.021 -
Genes or environment, what is important for the progression of chronic pancreatitis?
A commentary arguing that environmental factors, especially alcohol and tobacco, may influence chronic pancreatitis progression more than genetic variants, and urging matched exposure data to clarify gene–environment roles.
DOI: 10.1016/j.pan.2020.04.010 -
Allogeneic stem cell transplantation from variant-carrying family donors leads to long-term engraftment in Telomere Biology Disorders
A retrospective analysis of three Telomere Biology Disorder (TBD) cases shows hematopoietic stem cell transplantation (HSCT) from asymptomatic matched related donors carrying TBD-associated pathogenic variants can achieve sustained long-term engraftment, suggesting this may be f…
DOI: 10.1038/s41408-025-01348-z -
Clinical and metabolic phenotypes of Oxford Biobank subjects with variations in human flavin-containing monooxygenase 5 (FMO5)
A translational metabonomics study in 24 human female Oxford Biobank participants (12 with heterozygous FMO5 variants and 12 matched controls) using NMR-based urine/plasma profiling to test whether human FMO5 variation reproduces the lean/metabolic phenotypes and elevated urinar…
DOI: 10.1007/s11306-025-02308-1 -
Computational variant predictors for pharmacogenomics: from evaluation of single alleles to assessment of adverse drug reactions to antidepressants
Ensemble and gene-specific computational variant-effect predictors can match star-allele classifications, generalize to novel variants, and predict antidepressant-related adverse drug reactions in UK Biobank, enabling scalable genome-wide pharmacogenomic profiling.
DOI: 10.1038/s41397-026-00399-0 -
Role of thrombomodulin gene in Indian population with coronary artery disease
In an Indian case–control study, thrombomodulin (TM) gene variants and soluble TM (sTM) levels were examined in CAD patients and matched controls; overall TM variants were not associated with CAD, but the Ala455Val substitution showed a strong association with CAD in subjects ag…
DOI: 10.3109/1354750X.2012.706642 -
BNT162b2 Booster Vaccination Induced Immunity against SARS-CoV-2 Variants among Hemodialysis Patients
This study evaluates the effectiveness of the BNT162b2 booster vaccination in enhancing immunity against SARS-CoV-2 variants in hemodialysis patients compared to age-matched controls, revealing significant improvements in antibody titers and T-cell responses, but also highlighti…
DOI: 10.3390/vaccines10060967 -
OCTN and CARD15 gene polymorphism in Chinese patients with inflammatory bowel disease
This study genotyped NOD2/CARD15 (R702W, G908R) and OCTN1/ OCTN2 SNPs in Chinese Han inflammatory bowel disease patients (Crohn's disease and ulcerative colitis) and matched controls, and found no variants in any group, suggesting these polymorphisms are rare and not linked to I…
DOI: 10.3748/wjg.14.4923 -
The Effect of RBD-Based Vaccines on Covid-19 XBB 1.5 Subvariant
This study investigates the effects of monovalent RBD-based vaccines on the XBB 1.5 subvariant of COVID-19, revealing that while these vaccines can elicit immune responses, their effectiveness may be reduced due to mutations, thus recommending the use of bivalent vaccines where …
DOI: 10.23880/apct-16000213 -
Relative vaccine effectiveness of mRNA COVID-19 boosters in people aged at least 75 years during the spring-summer (monovalent vaccine) and autumn-winter (bivalent vaccine) booster campaigns: a prospective test negative case–control study, United Kingdom, 2022
Among adults aged 75 and older, spring-summer monovalent mRNA boosters and autumn-winter BA.1/ancestral bivalent boosters provided similar additional protection against COVID-19–related hospitalisation within 3 months of vaccination, supporting UK booster programs across two dis…
DOI: 10.2807/1560-7917.es.2023.28.48.2300173 -
Effectiveness of bivalent COVID-19 boosters against COVID-19 mortality in people aged 65 years and older, Australia, November 2022 to May 2023
In Australians aged 65+, recently administered bivalent boosters reduced COVID-19 mortality more than ancestral monovalent boosters during Nov 2022–May 2023, with strongest protection within 8–90 days and waning thereafter.
DOI: 10.2807/1560-7917.es.2023.28.47.2300603 -
Plasmodium falciparum Parasitemia Does Not Diminish Neutralizing Antibody Responses After mRNA COVID-19 Booster Vaccination in HIV-infected Adults
In adults living with HIV in western Kenya, subclinical Plasmodium falciparum parasitemia did not diminish neutralizing antibody responses to COVID-19 mRNA booster vaccines (monovalent or bivalent) compared with Pf-uninfected individuals, with robust antibody titers observed in …
DOI: 10.1093/infdis/jiaf398 -
Comparative Analysis of the Neutralizing Capacity of Monovalent and Bivalent Formulations of Betuvax-CoV-2, a Subunit Recombinant COVID-19 Vaccine, Against Various Strains of SARS-CoV-2
This study compares the neutralizing capacity of monovalent and bivalent formulations of the Betuvax-CoV-2 vaccine against various SARS-CoV-2 strains, revealing that while both formulations induce strong immune responses, the bivalent vaccine does not provide significant advanta…
DOI: 10.3390/vaccines12101200 -
XBB.1.5 spike protein COVID-19 vaccine induces broadly neutralizing and cellular immune responses against EG.5.1 and emerging XBB variants
Monovalent XBB.1.5 spike vaccine elicits broad neutralizing antibodies and Th1-biased cellular responses against XBB variants in mice and nonhuman primates, supporting a monovalent XBB.1.5 vaccine update for 2023-2024 boosters.
DOI: 10.1038/s41598-023-46025-y -
Immunogenicity of JN.1- and KP.2-Encoding mRNA COVID-19 Vaccines Against JN.1 Subvariants in Adult Participants
In adults previously vaccinated against COVID-19, an open-label phase 3b/4 study evaluated 50-µg monovalent mRNA-1273 vaccines encoding the JN.1 (mRNA-1273.167) or KP.2 (mRNA-1273.712) variants, showing robust neutralizing antibody responses against matched variants and cross-ne…
DOI: 10.1093/ofid/ofaf705 -
Antibody responses to SARS-CoV-2 variants LP.8.1, LF.7.1, NB.1.8.1, XFG, and BA.3.2 following KP.2 monovalent mRNA vaccination
This study evaluates neutralizing antibody responses after KP.2 monovalent mRNA vaccination against emergent SARS-CoV-2 variants, finding substantial immune escape by several Omicron-related variants and that vaccination-alone recipients showed broader cross-neutralization, high…
DOI: 10.1128/mbio.02901-25 -
Long-term immune responses to SARS-CoV-2 Omicron BA.4/5 mRNA booster in people living with HIV
This study prospectively characterizes the immune responses to the original-BA.4/5 bivalent SARS-CoV-2 mRNA booster in people living with HIV on effective ART, showing transient humoral and polyfunctional T cell boosts with superior BA.4/5-specific antibody responses compared to…
DOI: 10.1038/s43856-025-00799-6 -
LP.8.1-directed COVID-19 mRNA vaccines boost neutralizing antibodies and mitigate ancestral immune imprinting
Monovalent LP.8.1 mRNA booster in US adults elicited strong neutralizing antibodies against LP.8.1 and multiple JN.1 subvariants, markedly reducing ancestral immune imprinting and yielding the highest post-boost titers against the homologous LP.8.1 strain.
DOI: 10.64898/2026.01.03.697434 -
Mitigation of imprinted antibody responses in elderly COVID-19 highly vaccinated individuals
Repeated monovalent Omicron boosters broaden neutralising breadth across circulating SARS-CoV-2 variants in an elderly, highly vaccinated cohort while partially mitigating Wu-1 imprinting, though BA.3.2.2 escape remains substantial.
DOI: 10.64898/2026.05.21.725708 -
Recurrent waning of anti-SARS-CoV-2 neutralizing antibodies despite multiple antigen encounters
A longitudinal analysis of 516 participants across infection, primo-vaccination, boosted, and breakthrough infection groups shows recurrent waning of SARS-CoV-2 neutralizing antibodies with a plateau after multiple antigen encounters, implying ongoing boosting may be needed to s…
DOI: 10.1186/s12967-025-06837-0 -
Comparative analysis of humoral immunity kinetics following three COVID-19 vaccines in a multi-ethnic cohort of medical students and healthcare professionals across Malaysia
A multicenter prospective cohort study in Malaysia comparing the time-dependent humoral responses (anti-S IgG and Ig-RBD neutralization) after two-dose Comirnaty, Vaxzevria, and CoronaVac vaccines across a multiethnic medical student/healthcare professional population, highlight…
DOI: 10.1038/s41598-025-07895-6 -
The protective immunity induced by SARS-CoV-2 infection and vaccination: a critical appraisal
This review argues that SARS-CoV-2 infection and vaccination induce partial, dynamic protective immunity through coordinated antibody and T-cell responses, with reinfection risk reduced by about 80 percent, though responses are subject to cross-reactivity and antibody-dependent …
DOI: 10.37349/ei.2021.00014